A survey of US venture capital funds investing in biotechnology shows that the poor economy did not deter VC investment in biotechnology in 2002, but it is unclear what looms ahead.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
BioAbility, 2003 U.S. Biotechnology VC Directory: U.S. Venture Capital Companies and Contacts, 2003 (Thomson BioWorld, http://www.bioworld.com/, 2003).
National Venture Capital Association, survey released January 14, 2003 ((http://www.nvca.org/), 2003).
Marshall M. New breed of VCs banking on biotech. Mercury News, August 18, 2002.
VentureOne and Ernst & Young. Venture investment in healthcare highest since boom, information technology companies left with less than 1/2 the pie. Press release, July 26, 2002.
PricewaterhouseCoopers/Thomson. Venture Economics and National Venture Capital Association MoneyTree Survey. Investments by industry 1995–2003. Press release, January 14, 2003.
Satomi, D. & Van Brunt, J. Down, but not out: financial snapshot for December 2002. Signals Magazine, http://www.signalsmag.com/, 2002.
Glass, Cindy. ThinkEquity partners. Mapping the Financing Genome presentation, Research Triangle Park, NC, March 4, 2003.
Staff reporter. Though overall VC spending stumbles and falls, private equity shines on biotech. GenomeWeb, http://www.genomeweb.com/, June 28, 2002.
Burrill & Company. Biotech survives its toughest year ever. Press release, January 3, 2003.
Staff reporter. VCs flee genomics shops in Q3; bioinformatics providers hardest hit. GenomeWeb, http://www.genomeweb.com/, September 30, 2002.
Howard K. Ah, youth: tough times for start-up companies means toughing it out. GenomeWeb, http://www.genomeweb.com/, October 4, 2002.
BioAbility, 2003 European Biotechnology VC Directory: European Venture Capital Companies and Contacts, 2003 (Thomson BioWorld, http://www.bioworld.com/, 2003).
Acknowledgements
The authors thank Howard Wachtler and Dragan Cicic of QED Technologies and Jefferson Clarke of The Aurora Funds for their review and comments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dibner, M., Trull, M. & Howell, M. US venture capital for biotechnology. Nat Biotechnol 21, 613–617 (2003). https://doi.org/10.1038/nbt0603-613
Issue Date:
DOI: https://doi.org/10.1038/nbt0603-613
This article is cited by
-
The rise of European venture capital for biotechnology
Nature Biotechnology (2003)